300298 三诺生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)6.3499.18615.1383.8986.940
总资产报酬率 ROA (%)3.3464.6928.6292.6735.208
投入资产回报率 ROIC (%)4.1755.74810.1513.0155.375

边际利润分析
销售毛利率 (%)55.15354.05852.88859.96565.253
营业利润率 (%)11.9776.7769.5065.89811.721
息税前利润/营业总收入 (%)12.1917.33414.5087.30013.163
净利润/营业总收入 (%)9.6034.82512.4154.5329.274

收益指标分析
经营活动净收益/利润总额(%)85.726132.06471.831196.037143.699
价值变动净收益/利润总额(%)0.2770.2950.140-55.417-25.576
营业外收支净额/利润总额(%)-0.117-10.64130.244-0.7964.668

偿债能力分析
流动比率 (X)1.3911.6211.4482.2063.230
速动比率 (X)0.9481.1351.0431.7372.663
资产负债率 (%)39.76741.44246.04132.77129.643
带息债务/全部投入资本 (%)27.37329.21334.05819.434--
股东权益/带息债务 (%)243.741221.812177.687392.403430.298
股东权益/负债合计 (%)134.466125.339109.149204.659236.720
利息保障倍数 (X)53.5686.06316.4885.04015.170

营运能力分析
应收账款周转天数 (天)46.08846.42635.44533.8130.000
存货周转天数 (天)122.551125.25396.269122.5480.000